Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

In vivo disposition kinetics of CTI-1601

July 31, 2019

Editing modifiers, not disease gene, improves dystrophy symptoms

July 31, 2019

Microbiome metabolites modulate ALS

July 30, 2019

Alterity Therapeutics completes phase I study of PBT-434

July 30, 2019

Masitinib can slow the functional decline in ALS patients

July 30, 2019

FDA clears IND for EPX-100 for Dravet syndrome

July 29, 2019

New ketamine prodrugs presented by XW Laboratories

July 29, 2019

Phase III OPTIMUM study of ponesimod in relapsing MS meets primary endpoint

July 26, 2019

Novel pigenin derivative with anti-ischemic and neuroprotective effects following ischemia in rats

July 26, 2019

BioHaven opens enrollment in phase III study of BHV-3241 for multiple system atrophy

July 25, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...